Navigation Links
MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
Date:5/23/2012

HAYWARD, Calif., and SHANGHAI, May 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.

"This patent is expected to be the first of a series to issue," said Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx. "With a scarcity of new antibiotics in development and ever-increasing bacterial resistance, we believe that MRX-I, with its high antimicrobial potency and enhanced safety profile, could offer a valuable option for treatment of infections caused by multi-drug resistant Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE)." 

"We are pleased that the USPTO has affirmed MicuRx's intellectual property rights by granting this key patent for our first antibiotic candidate," added Mike Gordeev, Ph.D, chief scientific officer and executive vice president of MicuRx.

Multi-Drug Resistance: A Growing Global Public Health Crisis

Modern antibiotics have substantially reduced the threat posed by infectious diseases and contributed to a dramatic drop in mortality rates over the past 40 years. However, pathogenic bacteria resistant to current therapies have evolved over the years and become ubiquitous. The World Health Organization, Centers for Disease Control and the Infectious Disease Society of America have identified multi-drug resistant bacteria as a major public health threat today and into the future. According to the Center for Disease Control and Prevention, about 70 percent of U.S. hospital infections are resistant to at least one of commonly used antibiotics. In certain regions, the incid
'/>"/>

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... to anti-clotting drug, CHICAGO, March 29 ... dose of a medication that prevents blood clotting,significantly ... coronary interventions (PCI), according to a multicenter study,reported ... the SCAI,Annual Scientific Sessions in Partnership with ACC ...
... ,culotte, technique better?, CHICAGO, March 29 When ... of two coronary arteries -- or a,bifurcation lesion -- ... vessels without blocking the opening to the side branch. ... on which of,two techniques produces the best long-term results ...
Cached Medicine Technology:Tailored Clopidogrel Dosing Improves PCI Outcomes 2Tailored Clopidogrel Dosing Improves PCI Outcomes 3Stenting Techniques Vie in Branchpoint Lesions 2
(Date:4/14/2014)... Doctors at Henry Ford Hospital reached a medical ... replacement using a novel way to access the heart. ... United States performing the unique procedure called transcaval valve ... blood vessels. , Northern Michigan resident Viola Waller, 80, ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... Popular web information on colorectal cancer is too ... address the appropriate risks to and concerns of patients, ... , In a review of a dozen popular websites, ... cancer screening were written beyond the recommended sixth-grade reading ...
(Date:4/14/2014)... the molecule, called microRNA 135b, is a vital ,worker, ... growth of bowel cancers. , Drugs targeted at the ... mutations at once, while tests for it could identify ... , The research was carried out by an international ...
Breaking Medicine News(10 mins):Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2
... French . , Montreal, February 22, 2010 ... young immigrants. A new study published in the Journal ... children from multiethnic, disadvantaged, inner-city neighbourhoods are up to 3.5 ... an estimated 45,000 school-aged children immigrate to Canada with their ...
... URBANA - A University of Illinois researcher advises caution ... this country,s Latino adolescents and young adults. "When ... in a 90-minute program, the Latino students in my classes ... were right!" said Marcela Raffaelli, a U of I professor ...
... ... Boehringer Ingelheim (Canada) Ltd. , ... Toronto, Ontario, Canada (PRWEB) February 22, 2010 -- Dalton Pharma Services announces ... the agreement Dalton will continue to provide chemistry services in support of Boehringer,s pharmaceutical ...
... life, researchers say , MONDAY, Feb. 22 (HealthDay News) ... causes low energy levels and reduced quality of life, ... a new study suggests. , About 15 percent of ... late side effect of chemotherapy or radiation therapy. , ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 2Health News:Are Latino teens sexual risk takers? It's complicated, researcher says 3Health News:Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement 2Health News:Testicular Cancer Survivors May Have Hormone Deficiency 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 2Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 3Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 4Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 5Health News:Anshen + Allen Uses ArchiCAD to Transform Shipping Containers Into Clinics for the Developing World 6Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 2Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 3Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 4Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 5Health News:57 Year-Old Grandmother Travels to Atacama Desert to Run First of Four Ultramarathons for Charity 6
... , , The Shortyavailable with both Impact ... our face-to-face relationship with the scientific community generates ... pipetting easier and more effective., Shorter and ... Gets you closer to the working area ...
... Powerful and Flexible Impact And Impact2 Pipettors ... volume ranges, our single channel Impact and ... of any application. Engineered with the same ... multichannel line, these pipettors are equally easy ...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... The Finnpipette BioControl is a ... technology. A complete liquid handling system ... twelve interchangeable tip cone modules. All ... tip cone modules fit one handle. ...
Medicine Products: